BNTC · Benitec Biopharma Inc. · Executive Compensation
$8.87
+0.12 (+1.37%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$308.01M
Shares
34.88M
Volume · Oct 9
73.14K
Avg daily vol (3M)
153.61K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dr. Jerel Banks | M.D. Ph.D Chairman and Chief Executive Officer | $25,865,036 |
| Megan Boston | Chief Financial Officer, Secretary | $8,599,293 |
| Sophie Mukadam | Chief Operating Officer | $3,775,393 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dr. Jerel Banks | M.D. Ph.D Chairman and Chief Executive Officer | $3,159,337 |
| Megan Boston | Chief Financial Officer, Secretary | $1,438,577 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dr. Jerel Banks | M.D. Ph.D. Executive Chairman and Chief Executive Officer | $918,725 |
| Megan Boston | Executive Director | $469,457 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Jerel Banks | M.D. Ph.D. Executive Chairman and Chief Executive Officer | $799,964 |
| Megan Boston | Executive Director | $456,476 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Megan Boston | member of the Board | Resigned | 2026-05-29 |
| David Friedman | director | Appointed | 2026-05-29 |
| Dr. Sharon Mates | director | Appointed | 2025-11-03 |
| Megan Boston | Chief Financial Officer | Appointed | 2024-12-13 |
| Sophie Mukadam | Chief Operating Officer | Appointed | 2024-12-13 |
| Kishan "Kishen" Mehta | director | Appointed | 2024-07-01 |